EAMS scientific opinion: Avelumab in the treatment of bladder cancer

Study results show significant 7.1-month improvement in median overall survival with avelumab as first-line maintenance plus best supportive care (BSC) compared with BSC alone.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in